uniQure (NASDAQ:QURE) Shares Gap Up – Time to Buy?

uniQure N.V. (NASDAQ:QURE)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $47.86, but opened at $50.72. uniQure shares last traded at $47.5850, with a volume of 468,709 shares trading hands.

Analyst Ratings Changes

Several research analysts recently weighed in on QURE shares. Mizuho boosted their price target on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price on the stock in a research report on Wednesday, June 17th. Weiss Ratings restated a “sell (e+)” rating on shares of uniQure in a research note on Friday, June 26th. Royal Bank Of Canada increased their price target on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, June 18th. Finally, Leerink Partners lifted their price objective on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $65.00.

uniQure Price Performance

The firm’s 50 day moving average price is $44.50 and its two-hundred day moving average price is $29.90. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. The stock has a market cap of $3.24 billion, a PE ratio of -11.53 and a beta of 0.94.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same period last year, the business posted ($0.69) earnings per share. On average, research analysts expect that uniQure N.V. will post -3.74 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 164,429 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total transaction of $7,287,493.28. Following the sale, the chief executive officer directly owned 558,810 shares in the company, valued at approximately $24,766,459.20. The trade was a 22.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 30,000 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total value of $1,392,600.00. Following the sale, the insider owned 148,235 shares in the company, valued at approximately $6,881,068.70. The trade was a 16.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 385,584 shares of company stock valued at $16,737,722 in the last 90 days. Corporate insiders own 4.65% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Avoro Capital Advisors LLC grew its holdings in shares of uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares in the last quarter. State Street Corp lifted its stake in shares of uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after acquiring an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the period. California State Teachers Retirement System grew its position in uniQure by 6,641.2% during the 2nd quarter. California State Teachers Retirement System now owns 2,423,263 shares of the biotechnology company’s stock worth $111,615,000 after acquiring an additional 2,387,316 shares during the last quarter. Finally, Orbimed Advisors LLC grew its position in uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after acquiring an additional 1,398,749 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.